Investment Rating - The investment rating for the beauty and personal care industry is "outperforming the market" [4][22]. Core Insights - The fund allocation ratio for the beauty and personal care industry decreased to 0.14% in Q4 2025, down 0.06 percentage points from Q3 2025, indicating a continued low allocation status [1][3][9]. - The total market capitalization of the beauty and personal care industry reached 255.096 billion yuan in Q4 2025, reflecting a 10.43% decrease from Q3 2025 [1][9]. - The medical beauty sector remains in an over-allocated position, while personal care and cosmetics are in a low allocation zone [2][11]. Summary by Sections Industry Overview - In Q4 2025, the fund allocation ratio for personal care products was 0.03%, down 0.01 percentage points from Q3 2025, with an over-allocation ratio of -0.04% [2][13]. - The cosmetics sector saw a fund allocation ratio of 0.02% in Q4 2025, down 0.02 percentage points from Q3 2025, with an over-allocation ratio of -0.1% [2][13]. - The medical beauty sector's fund allocation ratio was 0.09% in Q4 2025, down 0.03 percentage points from Q3 2025, with an over-allocation ratio of 0.02% [2][13]. Individual Stocks - The top three stocks in the beauty and personal care sector by fund allocation in Q4 2025 were Jinbo Biological, Aimeike, and Baiya Shares, with a total heavy holding ratio of 0.05%, down 0.02 percentage points from Q3 2025 [2][15][19]. - Jinbo Biological had a heavy holding ratio of 0.0163%, Aimeike at 0.0156%, and Baiya Shares at 0.0040% in Q4 2025, all showing a decline compared to Q3 2025 [15][19]. Investment Recommendations - In the context of stabilizing the economy and expanding domestic demand, it is recommended to focus on: 1. Cosmetics and medical beauty: There is significant demand potential in the medium to long term, supported by regulatory policies favoring compliant companies [3][20]. 2. Personal care products: The growing emphasis on health and wellness among consumers suggests opportunities for leading companies with strong R&D capabilities [3][20].

以下为2025年度新质100创新企业榜： 360集团 爱美客 百川智能 柏垠生物 达梦数据 海光信息 华硼中子 极智嘉科技 佳杰云星 金山办公 君实生物 科曼医疗 莱芒生物 老来健康 凌雄科技 Mirxes觅瑞 墨芯人工智能 欧冶半导体 擎朗智能 週届日日 安恒信息 百度慧播星 北京人形 丹诺医药 海康威视 华为终端 剂泰科技 箭元科技 京北方 康盈半导体 快看漫画 蓝箭航天 理工雷科 蚂蚁集团 壓尔线程 默达生物 普瑞基准 深睿医疗 爱连健康 奧比中光 百利天恒 长生医疗 国泰海通证券 寒武纪 火石创造 加速进化 会蝶集团 京东科技 科大讯飞 快手科技 浪潮海岳HOM 立康生命科技 Medidata 魔法原子 纳安生物 阡视科技 深之蓝 1月30日，由经济观察报社举办的2025年度创新峰会成功举办。此次峰会以 "新质领航 创启未来" 为主题，汇聚多名企业家、学者及行业领袖，围 绕人工智能、数字化转型、机器人、生物医药等热点领域，分享前沿动态与创新实践。 随着全球产业竞争进入 "创新竞速、集群突破" 的新阶段，中国正以 "新质生产力" 突破传统增长路径 —— 人工智能重构产业效率、半导体芯片 打破技术壁垒、空 ...

证券之星消息，1月30日医疗美容板块较上一交易日下跌3.14%，爱美客领跌。当日上证指数报收于 4117.95，下跌0.96%。深证成指报收于14205.89，下跌0.66%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.07 | -1.92% | 12.54万 | 3883.90万 | | 920982 | 锦波生物 | 221.39 | -2.42% | 7085.98 | 1.58亿 | | 688363 | 华熙生物 | 44.83 | -3.20% | 4.64万 | 2.10亿 | | 300896 | 爱美客 | 139.73 | -3.22% | 3.76万 | 5.31亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出7658.45万元，游资资金净流入4438.38万元，散户 资金净流入3220.06万元。医疗美容板块个股资金流向见下表： | 代码 | | | | 名称 ｜主力净流入（元）｜主力净占比｜ ...

证券代码：300896 证券简称：爱美客 公告编号：2026-002 号 爱美客技术发展股份有限公司 关于公司控股子公司 REGEN Biotech, Inc.重大仲裁的进展公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 | | --- | | 记载、误导性陈述或重大遗漏。 | 重要提示： 1.2025 年 9 月 10 日，深圳国际仲裁院（以下简称"深国仲"）紧急仲裁员 曾就达透医疗器械（上海）有限公司（以下简称"达透公司"）提出的临时措施 申请作出《深圳国际仲裁院决定书》（（2025）深国仲涉外受 8781 号），决定 REGEN Biotech, Inc.（以下简称"REGEN 公司"）在本案仲裁裁决作出前，不 得自行在中国国内销售 AestheFill 产品、不得否认达透公司是 AestheFill 产 品在中国国内的独家经销商、不得拒绝并应继续向达透公司按协议约定供应该产 品。2026 年 1 月 29 日，REGEN 公司收到深国仲作出的《仲裁庭关于〈撤销临时 措施决定申请〉的决定》，仲裁庭决定不再实施由紧急仲裁员于 2025 年 9 月 10 日作出的前述《深圳国际 ...

证券日报网讯1月29日，爱美客（300896）在互动平台回答投资者提问时表示，公司2025年整体经营业 绩及核心产品数据尚处年报编制阶段，将按监管要求在2025年年报中披露。 ...

Core Insights - The medical beauty sector experienced a rise of 2.96% on January 29, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Medical Beauty Sector Performance - Ai Meike (300896) closed at 144.38, with a gain of 4.53%, trading volume of 56,700 shares, and a transaction value of 803 million [1] - Huaxi Biological (688363) closed at 46.31, up 1.47%, with a trading volume of 45,900 shares and a transaction value of 211 million [1] - Jinbo Biological (920982) closed at 226.88, up 1.35%, with a trading volume of 8,287 shares and a transaction value of 1.86 billion [1] - ST Meigu (000615) closed at 3.13, down 1.26%, with a trading volume of 103,100 shares and a transaction value of 32.32 million [1] Capital Flow Analysis - The medical beauty sector saw a net inflow of 105 million from main funds, while retail investors experienced a net outflow of 33.44 million [1] - Ai Meike had a main fund net inflow of 103 million, representing 12.77%, with retail outflows of 38.71 million [2] - Huaxi Biological had a main fund net inflow of 10.25 million, representing 4.86%, with retail outflows of 1.15 million [2] - Jinbo Biological had a main fund net inflow of 9.45 million, representing 5.09%, with retail inflows of 1.25 million [2] - ST Meigu had a main fund net outflow of 7.90 million, representing -24.43%, with retail inflows of 4.02 million [2]

Core Insights - New Oxygen announced multiple strategic initiatives, including the establishment of the Youth Selection Alliance with 14 upstream manufacturers and a strategic partnership with Sota [1][4] - The company received several prestigious certifications from Euromonitor International, including recognition for having the largest number of light medical beauty chain stores [5] Group 1: Strategic Initiatives - The Youth Selection Alliance aims to achieve win-win outcomes for upstream companies and consumers through collaboration in areas such as price-volume linkage, tiered supply, training, and product traceability [5] - New Oxygen's partnership with Sota includes a guarantee for the traceability of each Thermage treatment head, with a compensation policy for non-compliant equipment [5] Group 2: Supply Chain and Expansion - Since 2021, New Oxygen has invested 1 billion yuan in building its supply chain system, establishing 9 medical device sales companies and a network of 1 central warehouse and 8 forward warehouses across the country [5] - As of January 8, 2026, New Oxygen's clinics have achieved a cumulative treatment volume of 1 million across 50 stores in 16 cities [5] Group 3: Future Plans - The company plans to continue its conservative product selection strategy and launch multiple new products in the fields of phototherapy, water light, large injections, and health by 2026 [6] - New Oxygen aims to accelerate its offline expansion and recruitment of medical staff, with plans to add 35 new stores and increase the number of doctors to 500 and nursing staff to 1000 by the end of 2026 [6]

Core Viewpoint - The CEO of New Oxygen Group, Jin Xing, stated that the friction with upstream suppliers has not significantly impacted the company's business, despite some suppliers expressing concerns about the company's pricing strategy and product sourcing [1][2][6]. Group 1: Pricing Strategy and Market Impact - In September 2025, New Oxygen launched the "Youth Needle" product priced at 2999 yuan, which is significantly lower than the market price of over 10,000 yuan, disrupting the existing pricing structure of upstream manufacturers [1][6]. - Despite backlash from several upstream manufacturers, including claims of unauthorized product sourcing and training issues, sales of the "Youth Needle" reportedly surged in October, November, and December 2025, indicating strong consumer acceptance [2][6][7]. Group 2: Business Expansion and Partnerships - As of January 8, 2026, New Oxygen has established 50 clinics across 16 cities and achieved a cumulative treatment volume of 1 million [3][6]. - New Oxygen announced the formation of the "Youth Premium Alliance" with 14 upstream manufacturers, aiming to enhance collaboration through price-volume linkage, tiered supply, training, and product traceability [3][6]. Group 3: Industry Dynamics and Future Outlook - The medical beauty industry is experiencing a shift towards a buyer's market, with an increasing number of suppliers providing more options for medical institutions, which can now select long-term partners and customize products based on their needs [4][7]. - The industry has seen a significant increase in the issuance of medical device certifications, with 52 Class III medical device certificates issued in 2025, suggesting a growing supply landscape [4][7].

Core Viewpoint - Aimeike's stock price has shown a slight decline this year, with a recent increase of 2.01% on January 29, 2025, but overall performance indicates a downward trend in the past months, raising concerns about its financial health and market position [1][2]. Financial Performance - For the period from January to September 2025, Aimeike reported a revenue of 1.865 billion yuan, representing a year-on-year decrease of 21.49%. The net profit attributable to shareholders was 1.093 billion yuan, down 31.05% compared to the previous year [2]. - Cumulative cash dividends since Aimeike's A-share listing amount to 3.887 billion yuan, with 3.012 billion yuan distributed over the last three years [3]. Shareholder and Market Activity - As of January 20, 2025, Aimeike had 61,700 shareholders, an increase of 0.42% from the previous period. The average number of circulating shares per shareholder decreased by 0.42% to 3,379 shares [2]. - On January 29, 2025, Aimeike's stock price was 140.89 yuan per share, with a total market capitalization of 42.632 billion yuan. The trading volume was 314 million yuan, with a turnover rate of 1.08% [1]. Business Overview - Aimeike, established on June 9, 2004, and listed on September 28, 2020, specializes in the research, production, and sales of biomedical soft tissue repair materials. Its main revenue sources include solution injection products (57.27%), gel injection products (37.97%), and others [1]. - The company operates within the beauty care and medical aesthetics industry, focusing on medical beauty consumables, and is associated with concepts such as weight loss drugs and cosmetics [1]. Institutional Holdings - As of September 30, 2025, Aimeike's top ten circulating shareholders included Hong Kong Central Clearing Limited, holding 6.8295 million shares (a decrease of 151,300 shares), and Huabao Zhongzheng Medical ETF, holding 4.2589 million shares (a decrease of 802,100 shares) [3].

（编辑 姚尧） 证券日报网讯 1月28日，爱美客在互动平台回答投资者提问时表示，公司新品的终端销售、复购率、医 院进货数据等涉及商业和具体经营数据，公司未有单独的披露数据。公司严格按照法律法规的要求履行 信披义务。 ...